Eva Hurt‐Camejo

6.1k total citations
92 papers, 4.8k citations indexed

About

Eva Hurt‐Camejo is a scholar working on Surgery, Molecular Biology and Immunology. According to data from OpenAlex, Eva Hurt‐Camejo has authored 92 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Surgery, 31 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Eva Hurt‐Camejo's work include Atherosclerosis and Cardiovascular Diseases (24 papers), Lipoproteins and Cardiovascular Health (21 papers) and Adipokines, Inflammation, and Metabolic Diseases (18 papers). Eva Hurt‐Camejo is often cited by papers focused on Atherosclerosis and Cardiovascular Diseases (24 papers), Lipoproteins and Cardiovascular Health (21 papers) and Adipokines, Inflammation, and Metabolic Diseases (18 papers). Eva Hurt‐Camejo collaborates with scholars based in Sweden, United States and Netherlands. Eva Hurt‐Camejo's co-authors include Germán Camejo, Birgitta Rosengren, Olov Wiklund, Peter Sartipy, Göran Bondjers, Göran Bondjers, Jan Oscarsson, H. Peilot, Urban Olsson and Petri T. Kovanen and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Circulation Research.

In The Last Decade

Eva Hurt‐Camejo

88 papers receiving 4.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Hurt‐Camejo Sweden 42 1.8k 1.5k 1.2k 908 843 92 4.8k
Germán Camejo Sweden 42 2.0k 1.1× 1.5k 1.0× 1.1k 0.9× 1.0k 1.1× 1.1k 1.3× 113 5.1k
Bernardo L. Trigatti Canada 34 2.4k 1.4× 2.8k 1.9× 927 0.8× 834 0.9× 1.0k 1.2× 93 5.6k
Gordon A. Francis Canada 39 2.3k 1.3× 2.4k 1.6× 1.3k 1.1× 895 1.0× 843 1.0× 109 6.0k
Ewa Ninio France 37 1.4k 0.8× 1.2k 0.8× 1.0k 0.9× 507 0.6× 570 0.7× 103 4.1k
Lawrence W. Castellani United States 41 2.2k 1.2× 1.8k 1.2× 804 0.7× 541 0.6× 1.3k 1.5× 71 6.6k
Vladimir R. Babaev United States 37 2.5k 1.4× 1.4k 1.0× 1.7k 1.5× 782 0.9× 688 0.8× 69 5.5k
Colin H. Macphee United States 41 2.6k 1.5× 2.5k 1.6× 1.2k 1.1× 1.4k 1.5× 944 1.1× 90 7.1k
Pieter H.E. Groot Netherlands 38 1.8k 1.0× 1.6k 1.0× 1.1k 1.0× 756 0.8× 1.2k 1.4× 91 5.1k
Joy S. Frank United States 27 1.8k 1.0× 1.8k 1.2× 971 0.8× 545 0.6× 719 0.9× 40 4.6k
Thomas L. Innerarity United States 36 2.0k 1.1× 2.3k 1.5× 814 0.7× 1.3k 1.4× 1.6k 1.9× 54 5.1k

Countries citing papers authored by Eva Hurt‐Camejo

Since Specialization
Citations

This map shows the geographic impact of Eva Hurt‐Camejo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hurt‐Camejo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hurt‐Camejo more than expected).

Fields of papers citing papers by Eva Hurt‐Camejo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hurt‐Camejo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hurt‐Camejo. The network helps show where Eva Hurt‐Camejo may publish in the future.

Co-authorship network of co-authors of Eva Hurt‐Camejo

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Hurt‐Camejo. A scholar is included among the top collaborators of Eva Hurt‐Camejo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Hurt‐Camejo. Eva Hurt‐Camejo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pieterman, Elsbet, P. Hans, Magnus J. Johansson, et al.. (2021). Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. European Journal of Pharmaceutical Sciences. 161. 105776–105776. 10 indexed citations
2.
Berg, M, Konstantinos A. Polyzos, Hanna E. Agardh, et al.. (2019). 3-Hydroxyanthralinic acid metabolism controls the hepatic SREBP/lipoprotein axis, inhibits inflammasome activation in macrophages, and decreases atherosclerosis in Ldlr−/− mice. Cardiovascular Research. 116(12). 1948–1957. 41 indexed citations
3.
Sokolov, Victor, Gabriel Helmlinger, Catarina Nilsson, et al.. (2019). Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. Journal of Lipid Research. 60(9). 1610–1621. 17 indexed citations
4.
Aldi, Silvia, Ljubica Matic, Grégory Hamm, et al.. (2018). Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis. Molecular Therapy — Methods & Clinical Development. 10. 17–28. 17 indexed citations
5.
Hashimoto, Toru, Toshihiro Ichiki, Aya Watanabe, et al.. (2014). Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice. Vascular Pharmacology. 61(2-3). 49–55. 35 indexed citations
6.
Rosengren, Birgitta, et al.. (2012). HDL2 interferes with LDL association with arterial proteoglycans: A possible athero-protective effect. Atherosclerosis. 225(1). 115–120. 25 indexed citations
7.
Hurt‐Camejo, Eva, et al.. (2010). Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase. Journal of Lipid Research. 51(7). 1801–1809. 19 indexed citations
8.
López, Flor, et al.. (2010). High Plasma Phospholipase A2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes. Obesity. 18(10). 2023–2029. 22 indexed citations
9.
Soininen, Pasi, et al.. (2009). Phospholipase A2-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH. Atherosclerosis. 207(2). 352–359. 22 indexed citations
10.
Xiang, Hua, Jun Su, Elisabet Svenungsson, et al.. (2009). Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular disease. Scandinavian Journal of Rheumatology. 38(3). 184–189. 27 indexed citations
11.
Fogelstrand, Linda, et al.. (2008). Increased lipolysis by secretory phospholipase A2 group V of lipoproteins in diabetic dyslipidaemia. Journal of Internal Medicine. 264(2). 155–165. 17 indexed citations
12.
Drenos, Fotios, Simon R. Thompson, Jackie A. Cooper, et al.. (2007). Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5 , shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Human Molecular Genetics. 16(12). 1437–1444. 31 indexed citations
13.
Vallvé, Joan-Carles, Josefa Girona, Sebastián Paredes, Eva Hurt‐Camejo, & L. Masana. (2006). We-P12:310 TNF alpha -1031 T>C polymorphism is associated with elevated markers of oxidation and with smaller LDL size in subjects with rheumatoid arthritis. Atherosclerosis Supplements. 7(3). 414–414. 1 indexed citations
14.
Drenos, Fotios, Jackie A. Cooper, Simon R. Thompson, et al.. (2005). Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Human Molecular Genetics. 15(2). 355–361. 44 indexed citations
15.
Leinonen, Eeva, et al.. (2003). Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 166(2). 387–394. 224 indexed citations
16.
Sartipy, Peter, Germán Camejo, Lennart Svensson, & Eva Hurt‐Camejo. (2002). Phospholipase A2 Modification of Lipoproteins: Potential Effects on Atherogenesis. Advances in experimental medicine and biology. 507. 3–7. 10 indexed citations
17.
18.
Hurt‐Camejo, Eva, Germán Camejo, & Peter Sartipy. (2000). Phospholipase A2 and small, dense low-density lipoprotein. Current Opinion in Lipidology. 11(5). 465–471. 76 indexed citations
19.
Camejo, Germán, et al.. (1998). Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis. 139(2). 205–222. 258 indexed citations
20.
Sartipy, Peter, Berit Johansen, Germán Camejo, et al.. (1996). Binding of Human Phospholipase A2 Type II to Proteoglycans. Journal of Biological Chemistry. 271(42). 26307–26314. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Germán Camejo Breakdown of academic impact, for papers by Bernardo L. Trigatti Breakdown of academic impact, for papers by Gordon A. Francis Breakdown of academic impact, for papers by Ewa Ninio Breakdown of academic impact, for papers by Lawrence W. Castellani Breakdown of academic impact, for papers by Vladimir R. Babaev Breakdown of academic impact, for papers by Colin H. Macphee Breakdown of academic impact, for papers by Pieter H.E. Groot Breakdown of academic impact, for papers by Joy S. Frank Breakdown of academic impact, for papers by Thomas L. Innerarity
Rankless by CCL
2026